Europäische Union - Deutsch - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ipilimumab - melanoma; carcinoma, renal cell; carcinoma, non-small-cell lung; mesothelioma, malignant; colorectal neoplasms - antineoplastische mittel - melanomayervoy as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4.  yervoy in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. relative to nivolumab monotherapy, an increase in progression-free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression (see sections 4. 4 und 5. renal cell carcinoma (rcc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5. non-small cell lung cancer (nsclc)yervoy in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. malignant pleural mesothelioma (mpm)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)yervoy in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5. oesophageal squamous cell carcinoma (oscc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%.

Europäische Union - Deutsch - EMA (European Medicines Agency)

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antineoplastische mittel - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

lilly deutschland gesellschaft mit beschränkter haftung (3082352) - olanzapin - schmelztablette - teil 1 - schmelztablette; olanzapin (26581) 20 milligramm

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

lilly deutschland gesellschaft mit beschränkter haftung (3082352) - olanzapin - schmelztablette - teil 1 - schmelztablette; olanzapin (26581) 15 milligramm

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

lilly deutschland gesellschaft mit beschränkter haftung (3082352) - olanzapin - schmelztablette - teil 1 - schmelztablette; olanzapin (26581) 10 milligramm

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

lilly deutschland gesellschaft mit beschränkter haftung (3082352) - olanzapin - schmelztablette - teil 1 - schmelztablette; olanzapin (26581) 5 milligramm

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

eli lilly (suisse) sa - olanzapinum - überzogene tabletten - olanzapinum 5 mg, lactosum monohydricum 156 mg, hydroxypropylcellulosum, crospovidonum, magnesium stearas, cellulosum microcristallinum, hypromellosum, pellicule: carnauba-wachs, hypromellosum, e 171, macrogola, polysorbatum 80, für compresso dunst. - neuroleptikum - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

eli lilly (suisse) sa - olanzapinum - überzogene tabletten - olanzapinum 10 mg, lactosum monohydricum 312 mg, hydroxypropylcellulosum, crospovidonum, magnesium stearas, cellulosum microcristallinum, hypromellosum, pellicule: carnauba-wachs, hypromellosum, e 171, macrogola, polysorbatum 80, für compresso dunst. - neuroleptikum - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

eli lilly (suisse) sa - olanzapinum - überzogene tabletten - olanzapinum 2.5 mg, lactosum monohydricum 102.15 mg, hydroxypropylcellulosum, crospovidonum, magnesium stearas, cellulosum microcristallinum, hypromellosum, pellicule: carnauba-wachs, hypromellosum, e 171, macrogola, polysorbatum 80, für compresso dunst. - neuroleptikum - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

eli lilly (suisse) sa - olanzapinum - überzogene tabletten - olanzapinum 15 mg, lactosum monohydricum 178.2 mg, hydroxypropylcellulosum, crospovidonum, cellulosum microcristallinum, magnesium stearas, hypromellosum, pellicule: carnauba-wachs, lactosum monohydricum 4.9 mg, hypromellosum, e 171, triacetinum, e 132, für compresso dunst. - neuroleptikum - synthetika